NCT05155969

Intravenous Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery

Evaluating the Effect of Subanaesthetic Dose of Esketamine on Prevention of Postoperative Depression in Patients Undergoing Cardiac Surgery：a Randomized, Double-blind, Placebo-controlled Pilot and Feasibility Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Anshi Wu · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Esketamine is a general anesthetic with anti-depressant effects at subanaesthetic doses. This study hypothesized that intraoperative administration of ketamine would prevent or mitigate postoperative depressive symptoms in surgical patients.

Detailed description

Single subanaesthetic doses of i.v. esketamine may significantly improve symptoms in psychiatric patients with major depression. In patients undergoing cardiac surgery, postoperative depressive symptoms are common. This study hypothesizes that low-dose esketamine has a preventive effect on postoperative depression. However, evidence in this aspect is insufficient. The purpose of this study is to investigate the effect of a subanaesthetic dose of ketamine on POD for patients undergoing cardiac surgery.

Conditions

• Postoperative Depression

Interventions

Type	Name	Description
DRUG	Esketamine	esketamine (0.3 mg/kg in 100 ml normal saline) is intravenously infused 40 minutes before anesthesia induction
DRUG	Normal saline	Normal saline will be administrated intravenously at the dural opening, with a total dose of 0.5 ml/kg and continual infusion for 40 minutes.

Timeline

• Start date: 2021-12-01
• Primary completion: 2021-12-05
• Completion: 2022-12-15
• First posted: 2021-12-14
• Last updated: 2021-12-14

Locations

2 sites across 1 country: China